Study Details

Back
Study ID 9785-CL-0011
Study Title A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (formerly MDV3100) in Combination with Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Clinicaltrials.gov Identifier NCT01650194
Compound Name MDV3100 / enzalutamide
Medical Indication or Disease Prostate cancer
Study Sponsor Astellas Pharma Global Development, Inc.
Collaborator Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Study Start Date 09-Jul-2012
Study Completion Date 04-Jan-2018
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS